Clinical Topics   /   Oncology

VA Study Indicates That Location Matters in Colon Cancer Survival

by Annette Boyle
June 1, 2018

ALBANY, NY — More than 95,000 Americans develop colon cancer, making it the third most common cancer in the U.S., excluding skin cancers. While stage and histology are known to affect prognosis, does it matter where tumors first occur in the massive organ?

According to research released in conjunction with this weekend’s 2018 American Society of Clinical Oncology Annual Meeting, location makes a significant difference.1

A team of researchers from the Stratton VAMC and the Albany Medical College, both in Albany, NY, analyzed data from the National VA Cancer Cube Registry to detect differences in the course and characteristics of colon cancer based on tumor sidedness. They defined right-sided colon cancer as tumors that first appeared in the region from the cecum to the hepatic flexure. Left-sided colon cancer included those that originated from the splenic flexure to the rectum. Transverse cancer included all those that arose between the flexures.

The researchers identified 65,940 total cases of colon cancer diagnosed in veterans who received care at VA facilities between 2001 and 2015. Of those, they classified 30.1% as right-sided and 58.8% as left-sided colon cancers.

Right-sided colon cancer arose more frequently in women, in whom it accounted for 36.3% of cases, compared to 30.1% of cases in men. Right-sided colon cancer also represented the majority (51.8%) of cases in patients over the age of 70, while about one-third of older patients developed left-sided colon cancer. Left-sided colon cancer occurred slightly more often in whites (59.4%) than in blacks (56%).

Right-sided colon cancer was more likely to have reached an advanced stage prior to diagnosis; 60.84% of cases were diagnosed as stage II-IV. In left-sided colon cancer, by contrast, nearly half of cases (48.2%) were stage I at diagnosis.

Notably, right-sided colon cancer has a worse one-year survival rate than left-sided colon cancer. The majority of patients with right-sided colon cancer (50.5%) died within the first year after diagnosis compared to 42.2% of those with left-sided colon cancer.


1Azar I, Esfandiarifard S, Virk G, et al. Primary tumor sidedness in colorectal cancer at VA hospitals: A nation-wide study. J Clin Oncol 36, 2018 (suppl; abstr e15638).

Related Articles

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

Oncology

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article

Oncology

Military Risks for Ocular Surface Squamous Neoplasia

MIAMI—While a variety of risk factors have been evaluated in ocular surface squamous neoplasia, few studies have assessed risk factors specific to the armed forces veteran population. A report in the journal Eye and Vision... View Article

Oncology

Antibiotics Appear to Inhibit Tumor Activity in CTCL

AARHUS, DENMARK—Do CD4 T cell responses to  Staphylococcus aureus inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T cell lymphoma? A prospective study in the journal Blood examined that question, exploring the... View Article

Oncology

Lower Dose Cisplatin Preferable in Squamous Cell Carcinoma

PHILADELPHIA—Chemoradiotherapy is commonly used for nonoperative treatment of locally advanced head and neck squamous cell carcinoma. The issue, according to a recent study, is that the standard dose of 100 mg/m2 cisplatin every three weeks is... View Article

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up